The lab report says 118. The reference range printed next to it says "desirable: below 130". No asterisk, no bold red flag. So everything is fine — isn't it?
Not necessarily. That printed range is a population average, not a target set for your risk. And in 2026 the goalposts moved.
What changed this year
The 2026 ACC/AHA dyslipidemia guideline went back to naming absolute LDL numbers to aim for, instead of only asking for a percentage reduction:
- Higher-risk adults: LDL cholesterol below 70 mg/dL (and non-HDL below 100)
- Borderline-to-intermediate risk: LDL below 100 mg/dL (and non-HDL below 130)
Risk is now estimated with a newer calculator that reports both 10-year and 30-year risk. That second number matters for anyone in their thirties and forties, because a modest 10-year risk can sit on top of a substantial lifetime risk — and lifetime risk is what quietly builds plaque through the years nobody is watching.
The guiding idea is simple: lower, and earlier. Damage to artery walls accumulates by dose and duration, not by whether a number crossed a line printed on a report.
Why this matters more for people of Indian origin
South Asians tend to develop coronary disease a decade earlier than Western populations, often at lower body weight, and frequently with a pattern the standard report does not display well — normal-looking LDL with high triglycerides, low HDL and a high number of small particles. A "normal" lipid profile does not rule this out.
Two tests worth knowing about
- Lipoprotein(a) — the 2026 guideline recommends measuring it at least once in a lifetime. It is inherited, it does not move meaningfully with diet or exercise, and it is a common reason for a heart attack in someone whose other numbers looked unremarkable. One test, one answer, for life.
- Apolipoprotein B — counts the actual number of harmful particles, which can be high even when LDL looks acceptable, particularly in people with diabetes or high triglycerides.
A coronary calcium score may also be used to settle the question in someone genuinely in between — it shows whether plaque has already formed rather than estimating whether it might.
What to do with a "borderline" report
- Bring the actual report to a consultation instead of a verbal number. Triglycerides, HDL and non-HDL matter as much as the LDL line.
- Have your risk calculated properly, including family history of early heart disease — a father, brother, mother or sister affected before 55 or 65 changes the conversation.
- Do the lifestyle work seriously: it is the foundation, and for many it is enough. But if LDL stays above your target despite it, that is a biological fact about how your liver handles cholesterol, not a personal failure.
- If medicine is advised, understand the plan: statins remain first line, with ezetimibe, bempedoic acid or injectable PCSK9-directed therapy added when the target is not reached. Muscle aches deserve review, not silent discontinuation.
- Repeat the profile after the interval you are given, so the plan is judged on a number rather than on a hope.
The one-line version
"Normal for the lab" and "low enough for your heart" are two different statements. Which one applies to you depends on your risk — and that takes a conversation, not a reference range.